Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT NASDAQ:CAPR NASDAQ:ELDN NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACAPRCapricor Therapeutics$19.12-6.0%$26.60$4.30▼$40.37$1.18B0.421.63 million shs1.49 million shsELDNEledon Pharmaceuticals$3.84-4.5%$3.80$1.35▼$4.60$310.30M0.951.85 million shs757,356 shsSDGRSchrodinger$15.60-4.1%$14.84$10.94▼$23.75$1.20B1.621.30 million shs1.28 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%CAPRCapricor Therapeutics-1.60%-8.54%-23.84%-41.17%+183.43%ELDNEledon Pharmaceuticals-0.74%-4.51%+17.20%+7.77%+4.42%SDGRSchrodinger+0.87%+1.12%+11.44%+34.91%-20.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACAPRCapricor Therapeutics$19.12-6.0%$26.60$4.30▼$40.37$1.18B0.421.63 million shs1.49 million shsELDNEledon Pharmaceuticals$3.84-4.5%$3.80$1.35▼$4.60$310.30M0.951.85 million shs757,356 shsSDGRSchrodinger$15.60-4.1%$14.84$10.94▼$23.75$1.20B1.621.30 million shs1.28 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%CAPRCapricor Therapeutics-1.60%-8.54%-23.84%-41.17%+183.43%ELDNEledon Pharmaceuticals-0.74%-4.51%+17.20%+7.77%+4.42%SDGRSchrodinger+0.87%+1.12%+11.44%+34.91%-20.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/ACAPRCapricor Therapeutics 2.90Moderate Buy$53.67180.68% UpsideELDNEledon Pharmaceuticals 2.40Hold$9.67151.74% UpsideSDGRSchrodinger 2.33Hold$20.2529.81% UpsideCurrent Analyst Ratings BreakdownLatest ELDN, CAPR, CALT, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026CAPRCapricor Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/15/2026CAPRCapricor Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026CAPRCapricor Therapeutics Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/14/2026SDGRSchrodinger Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $17.005/13/2026CAPRCapricor Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74CAPRCapricor Therapeutics$22.27M49.72N/AN/A$5.53 per share3.46ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.35 per shareN/ASDGRSchrodinger$255.87M4.50N/AN/A$4.94 per share3.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ACAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)ELDNEledon Pharmaceuticals-$45.62M-$0.77N/AN/AN/AN/A-116.97%-41.91%8/13/2026 (Estimated)SDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)Latest ELDN, CAPR, CALT, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ELDNEledon Pharmaceuticals-$0.19N/AN/AN/AN/AN/A8/11/2026Q2 2026CAPRCapricor Therapeutics-$0.58N/AN/AN/A$2.08 millionN/A8/5/2026Q2 2026SDGRSchrodinger-$0.60N/AN/AN/A$47.20 millionN/A5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22-$0.33-$0.11-$0.33N/AN/A5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59CAPRCapricor TherapeuticsN/A8.428.42ELDNEledon PharmaceuticalsN/A8.448.44SDGRSchrodingerN/A2.742.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%CAPRCapricor Therapeutics21.68%ELDNEledon Pharmaceuticals56.77%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%CAPRCapricor Therapeutics9.20%ELDNEledon Pharmaceuticals9.60%SDGRSchrodinger10.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionNo DataCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableELDNEledon Pharmaceuticals1077.19 million69.78 millionOptionableSDGRSchrodinger79073.82 million66.37 millionOptionableELDN, CAPR, CALT, and SDGR HeadlinesRecent News About These CompaniesSumitomo Mitsui Trust Group Inc. Trims Stock Holdings in Schrodinger, Inc. $SDGRJuly 14 at 5:04 AM | marketbeat.comSchrödinger: Surviving, If Not Thriving, In The Tricky AI Drug Discovery FieldJuly 8, 2026 | seekingalpha.comSchrodinger, Inc. (NASDAQ:SDGR) Receives Consensus Recommendation of "Hold" from BrokeragesJuly 6, 2026 | americanbankingnews.comA Look at Schrodinger Inc (SDGR) After 6.6% Decline -- GF Value $26.32 vs Price $16.25June 30, 2026 | gurufocus.comWhat Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal?June 23, 2026 | finance.yahoo.comA Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26.55 vs Price $14.15May 28, 2026 | gurufocus.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 22, 2026 | businesswire.comSchrödinger Balances Growth and Losses in Earnings CallMay 20, 2026 | tipranks.com7 Healthcare AI Stocks Under $50 With Huge Upside PotentialMay 18, 2026 | 247wallst.comSchrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comEarnings Update: Schrödinger, Inc. (NASDAQ:SDGR) Just Reported And Analysts Are Trimming Their ForecastsMay 8, 2026 | finance.yahoo.comSchrödinger (SDGR) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comA Look At Schrödinger (NasdaqGS:SDGR) Valuation After Q1 Earnings And Hosted AI Software PushMay 6, 2026 | finance.yahoo.comSchrödinger, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6, 2026 | seekingalpha.comSchrödinger, Inc. (SDGR) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSchrödinger Earnings Call: Growth Now, Profits LaterMay 5, 2026 | tipranks.comSchrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comSchrödinger Reports First Quarter 2026 Financial ResultsMay 5, 2026 | businesswire.comHere’s What the Street Thinks About Schrödinger (SDGR)May 5, 2026 | insidermonkey.comSchrodinger: AI Threat Is Looming Large (Rating Downgrade)April 22, 2026 | seekingalpha.comSchrödinger to Announce First Quarter 2026 Financial Results on May 5April 21, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026SK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026Capri's Turnaround Is Taking Shape, But Is the Stock a Buy Yet?By Jennifer Ryan Woods | June 28, 2026ELDN, CAPR, CALT, and SDGR Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 07/15/2026Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Capricor Therapeutics NASDAQ:CAPR$19.12 -1.23 (-6.04%) Closing price 04:00 PM EasternExtended Trading$19.20 +0.08 (+0.42%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Eledon Pharmaceuticals NASDAQ:ELDN$3.84 -0.18 (-4.48%) Closing price 04:00 PM EasternExtended Trading$3.87 +0.03 (+0.78%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Schrodinger NASDAQ:SDGR$15.60 -0.67 (-4.12%) Closing price 04:00 PM EasternExtended Trading$15.44 -0.16 (-1.03%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
